Paloma Partners’s Nektar Therapeutics NKTR Stock Holding History

Paloma Partners’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-653	Closed	-$597K	–	1626
2018 Q3	$597K	Buy	+653	New	+$557K	0.01%	956

Other funds holding NKTR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Paloma Partners's NKTR Position: Q3 2024 in Review

Paloma Partners sold out of Nektar Therapeutics (NKTR) in Q3 2024, closing a stake of 3,682 shares — an estimated $68.5K sold.

Paloma Partners first reported a position in NKTR in Q3 2013 and held it in 12 quarters. The position peaked at $20.3M in Q2 2018. 138 funds tracked by Wall St. Rank hold NKTR as of Q3 2024.

Paloma Partners reported no remaining Nektar Therapeutics position as of Q3 2024 after selling out during the quarter.
Paloma Partners sold 3,682 Nektar Therapeutics shares in Q3 2024, an estimated $68.5K.
Paloma Partners first reported a position in Nektar Therapeutics in Q3 2013 and held it in 12 quarters.
Paloma Partners's Nektar Therapeutics position peaked at $20.3M in Q2 2018.
138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.